News & Events

• September 14, 2014
  

  The Patient-Reported Outcome (PRO) Consortium Lessons Learned Along the Path to PRO Instrument Qualification

  Hayes RP, Blum SI, Gordon MF, Piault E, Burke LB, Slagle AF, Coons SJ. The Patient-Reported Outcome (PRO) Consortium Lessons Learned Along the Path to PRO Instrument Qualification. Therapeutic Innovation & Regulatory Science. 2015;49(1):132–8.

   

• July 1, 2014
  

  Coalition Against Major Diseases/European Medicines Agency Biomarker Qualification Of Hippocampal Volume For Enrichment Of Clinical Trials In Predementia Stages Of Alzheimer’s Disease

• April 1, 2014
  

  Advancing the Portfolio of Tuberculosis Diagnostics, Drugs, Biomarkers, and Vaccines

  Zumla AI, Schito M, Maeurer M. Advancing the Portfolio of Tuberculosis Diagnostics, Drugs, Biomarkers, and Vaccines. The Lancet Infectious Diseases. 2014 Apr;14(4):267–9.

• April 1, 2014
  

  Operationalizing Hippocampal Volume as an Enrichment Biomarker for Amnestic Mild Cognitive Impairment Trials: Effect of Algorithm, Test-Retest Variability, and Cut Point on Trial Cost, Duration, and Sample Size

• April 1, 2014
  

  New Antituberculosis Drugs, Regimens, and Adjunct Therapies: Needs, Advances, and Future Prospects

  Zumla AI, Gillespie SH, Hoelscher M, Philips PPJ, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. New Antituberculosis Drugs, Regimens, and Adjunct Therapies: Needs, Advances, and Future Prospects. The Lancet Infectious Diseases. 2014 Apr;14(4):327–40.